Rozanolixizumab improved symptoms in people with generalised myasthenia gravis in the MycarinG clinical study: a Plain Language Summary of Publication

Daily self-injection of zilucoplan improved symptoms in people with generalized myasthenia gravis in the RAISE clinical study: a Plain Language Summary of Publication

Safety and efficacy of chronic weekly rozanolixizumab in generalized myasthenia gravis: the randomized open‑label extension MG0004 study

Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: Results from the Phase 3 MycarinG study and an open-label extension

Subcutaneous zilucoplan: evaluation of reproductive toxicology

Rozanolixizumab in generalized myasthenia gravis: Pooled analysis of the Phase 3 MycarinG study and two open-label extensions

Evaluation of the effect of rozanolixizumab on pregnancy outcomes and pre- and postnatal development in cynomolgus monkeys

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Neonatal Fc Receptor Inhibitor Rozanolixizumab: An Ethnic Sensitivity Study in Healthy Japanese, Chinese, and White Participants

Usability of the zilucoplan prefilled syringe for the treatment of generalized myasthenia gravis: insights from a human factors validation study

Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration